Oncology and Hematology News and Journal Articles
Recent Content
The classification of diffuse large B-cell lymphoma into three distinct molecular diseases--germinal center B-cell–like subtype, an activated B-cell–like subtype, and a primary mediastinal B-cell lymphoma subtype--has laid the foundation for the development of new agents and novel strategies that target individual subtypes.
Case Studies | April 15, 2014
| Oncology Journal,
Genitourinary Cancers,
Kidney CancerBy
Rodrigo Donalisio Da Silva, MD,
Wilson R. Molina, MD,
Diedra Gustafson,
Leticia Nogueira,
Shalini Tayal, MD,
Francisco G. La Rosa, MD, and
Fernando J. Kim, MD A 60-year-old man was incidentally found to have a large right renal mass during a CT scan with and without intravenous and oral contrast ordered by his primary care physician to evaluate mild right side abdominal discomfort and hepatomegaly.
Men who used sildenafil (Viagra) had an 84% increased risk for developing melanoma, even after adjusting for known risk factors, according to the results of a prospective study.
This review will include discussion of the role of radiation therapy for osseous metastases and metastatic spinal cord compression, as well as the use of radiopharmaceuticals for painful osseous metastases.
In order to achieve maximum survival of patients with metastatic castration-resistant prostate cancer, the judicious use of all available effective agents and modalities is required. Both EBRT and radium-223 are effective at relieving pain, but both may decrease bone marrow function.
There is no question that radiopharmaceuticals have a role in the management of patients with metastatic bone disease. There is also no question that fractionated external beam radiotherapy (EBRT) is highly effective and generally well tolerated when delivered with large open or focal fields.
This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings—settings in which tremendous progress has been made.
At the ACCC annual meeting, Jessica Turgon, MBA, from ECG Management Consultants discusses how and why providers and payers are beginning to work together to explore alternate payment models in oncology.
At the ACCC 40th Annual National Meeting, David Evans, RN, MSN, MBA, discussed some of the top reimbursement issues that cancer centers face when it some to clinical trials.
Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II
Major studies looking at breast cancer screening with mammography may have more consistent findings than previously thought.
In this interview we preview the 2014 annual meeting of the Association of Community Cancer Centers with Matthew Farber, director of provider economics and public policy for the association.
In this interview we discuss the role of early treatment, active surveillance, and watchful waiting in patients with PSA-detected early-stage prostate cancer.
In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.
In this interview, we discuss the current state of pancreatic cancer management, and look toward trials to further define the best course of treatment for this deadly disease.
